Status:
TERMINATED
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Lead Sponsor:
Pfizer
Conditions:
Focal Segmental Glomerulosclerosis (FSGS)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.
Eligibility Criteria
Inclusion
- Adults age 18 years and older who have a confirmed biopsy diagnosis of FSGS.
- Estimated glomerular filtration rate (eGFR) greater than or equal to 45 ml/min/1.73 m2. If eGFR is 30 - 45 ml/min/1.73 m2, a recent biopsy (within 12 months prior to Screening) must demonstrate \< 50% tubulointerstitial fibrosis.
- Urine protein:creatinine ratio (UPCR) greater than 1.5 g/g at screening.
- Treated with at least one but not more than 3 classes of immunosuppressants either alone or in combination, or has a contraindication to use of an immunosuppressant or is intolerant to an immunosuppressant per investigator judgment.
Exclusion
- Diagnosis of collapsing FSGS.
- Advanced chronic changes on renal biopsy as evidenced by greater than 50% tubulointerstitial fibrosis.
- Organ transplant.
- History of malignancy, with the exception of basal or squamous cell carcinoma that has been treated and fully resolved for a minimum of 5 years.
- Body mass index (BMI) greater than 45 kg/m2.
- Subjects with a history of prior treatment with or use of interferon, lithium, pamidronate, mTOR inhibitors (eg, sirolimus), testosterone/anabolic steroids, anthracycline (eg, doxorubicin), heroin.
Key Trial Info
Start Date :
October 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2023
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT03448692
Start Date
October 15 2018
End Date
February 14 2023
Last Update
April 18 2024
Active Locations (110)
Enter a location and click search to find clinical trials sorted by distance.
1
The Kirklin Clinic of University Alabama Birmingham Hospital
Birmingham, Alabama, United States, 35233
2
Investigational Drug Service Pharmacy UAB Hosptial
Birmingham, Alabama, United States, 35249
3
Clinical Research Unit at UAB Hospital
Birmingham, Alabama, United States, 35294
4
UAB Nephrology Research Clinic at Paula Building
Birmingham, Alabama, United States, 35294